Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Sinovac Announces Success for Phase I Trial of EV71 Vaccine

publication date: May 25, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sinovac Biotech reported positive results from a Phase I trial of its vaccine for human enterovirus 71 (EV71), the virus that causes Hand, Foot, and Mouth Disease (HFMD). Sinovac needs to expand its portfolio of vaccines to regain profitability. The company prospered in 2009-10 on its H1N1 flu vaccine, but those revenues have disappeared as Chinese consumers became afraid of vaccine-borne illnesses. Sinovac also announced recently that it is moving closer to production of an animal rabies vaccine. More details....

Stock Symbol: (NSDQ: SVA)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners